Read more
Informationen zum Autor Miles Fisher, Consultant Physician, Glasgow Royal Infirmary John McMurray, Professor of Medical Cardiology, British Heart Foundation Cardiovascular Research Centre, University of Glasgow and Honorary Consultant Cardiologist, Western Infirmary, Glasgow Klappentext With cardiovascular disease becoming the most common cause of death in people with diabetes, interest in the assessment and treatment of heart disease in these patients has been reawakened. This book examines developing topics from a largely cardiological perspective, covering both pharmacological and non-pharmacological interventions.The DIGAMI study on the use of intravenous insulin infusion at the time of myocardial infarction (MI) has stimulated a large number of discussion papers on the best treatment of MI in the diabetic patient. The UKPDS has shown that treatment of Type 2 diabetes does not reduce cardiovascular end-points significantly, but that aggressive treatment of blood pressure can do so. In addition, sub-group analysis from several large cardiovascular trials has shown that treatment with statins, anti-platelet therapy, ACE inhibitors and other drugs will also reduce cardiovascular events in people with diabetes. Zusammenfassung With cardiovascular disease becoming the most common cause of death in people with diabetes, interest in the assessment and treatment of heart disease in these patients has been reawakened. This book examines developing topics from a largely cardiological perspective, covering both pharmacological and non-pharmacological interventions.The DIGAMI study on the use of intravenous insulin infusion at the time of myocardial infarction (MI) has stimulated a large number of discussion papers on the best treatment of MI in the diabetic patient. The UKPDS has shown that treatment of Type 2 diabetes does not reduce cardiovascular end-points significantly, but that aggressive treatment of blood pressure can do so. In addition, sub-group analysis from several large cardiovascular trials has shown that treatment with statins, anti-platelet therapy, ACE inhibitors and other drugs will also reduce cardiovascular events in people with diabetes. Inhaltsverzeichnis List of contributors. Introduction. 1. Epidemiology of vascular disease in diabetes (Susan Laing). 1.1 Introduction. 1.2 The Role of Epidemiological Studies. 1.3 Cohort Studies of People with Diabetes. 1.4 Cardiovascular Disease and Diabetes. 1.5 Mortality from Coronary Heart Disease. 1.6 Mortality from Cerebrovascular Disease. 1.7 Discussion. References. 2. Pathogenesis of atherosclerosis and vascular disease in type 2 diabetes (Naveed Sattar and Alistair Cormack). 2.1 Introduction. 2.2 What is Insulin Resistance? 2.3 Dyslipidaemia and Type 2 Diabetes. 2.4 Hypertension. 2.5 Endothelial Dysfunction and Type 2 Diabetes. 2.6 Inflammation. 2.7 Adipokines - Adiponectin. 2.8 Haemostatic Changes in Type 2 Diabetes. 2.9 Hyperinsulinaemia. 2.10 Role of Hyperglycaemia. 2.11 Metabolic Syndrome as a Link between Insulin Resistance and CVD? 2.12 Effects of Anti-diabetic Drugs on Risk Factor Pathways. 2.13 Conclusions. References. 3. Coronary heart disease and diabetes (Colin Berry, Miles Fisher and John McMurray). 3.1 Nature of Coronary Heart Disease in Diabetes. 3.2 Presentation of CHD in Diabetes. 3.3 Non-invasive Investigation. 3.4 Pharmacological Treatment of CHD in People with Diabetes. 3.5 Coronary Revascularisation in Diabetes. 3.6 Stents for Coronary Artery Disease in Diabetes. 3.7 Drug-eluting Stents. 3.8 Drug Therapy and PCI in Diabetic Patients. 3.9 Conclusions. References. 4. Diabetes and acute coronary syndromes (Colin Berry, Miles Fisher and Jo...
